NEWS & MEDIA

Hemogenyx Pharmaceuticals Plc – Director / PDMR Shareholding

12 February 2018

Hemogenyx Pharmaceuticals Plc (LSE: HEMO), the biotechnology company developing novel therapies to transform bone marrow and blood stem cell transplantation, announces that it has been advised that on 9 February 2018 Adrian Beeston, Non-Executive Director, purchased 200,000 ordinary shares of £0.01 each in the Company (“Ordinary Shares“) at a price of 2.1p per share. Following this transaction Mr Beeston now has an interest in 6,331,969 Ordinary Shares, representing approximately 1.78 per cent. of the Company’s issued share capital.

 

The Notification of Dealing Form provided in accordance with the requirements of MAR in relation to the transactions listed above are set out below:

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

 

Name

 

 

Adrian Beeston

 

2

 

Reason for the notification

 

a)

 

 

Position/status

 

 

Non-executive Director

 

b)

 

 

Initial notification /Amendment

 

 

Initial notification
 

3

 

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

 

a)

 

 

 

Name

 

 

Hemogenyx Pharmaceuticals Plc
 

b)

 

 

 

LEI

 

 

n/a
4

 

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

 

 

 

 

a)

 

 

Description of the financial instrument, type of instrument

 

Ordinary shares of £0.01 each
Identification code ISIN GB00BYX3WZ24
 

b)

 

 

 

Nature of the transaction

 

 

Purchase of Ordinary Shares
c)

 

Price(s) and volume(s)
Price(s) Volume(s)
2.1p 200,000
 

 

d)

 

 

Aggregated information

 

– Aggregated volume

 

N/A – single transaction

– Price
 

e)

 

 

 

Date of the transaction

 

 

9 February 2018
 

f)

 

 

 

Place of the transaction

 

 

London Stock Exchange

 

This information is provided by RNS

The company news service from the London Stock Exchange